BIOLASE, INC: management transactions · United States · SEC (Form 4)

About BIOLASE, INC

BIOLASE, INC. is a United States-based medical device company listed on the NASDAQ (ticker: BIOL). The company operates in the dental technology niche, with a core focus on laser systems used in dentistry and, to a lesser extent, adjacent medical applications. Its business model centers on designing, manufacturing, marketing, and selling laser-based equipment to dental professionals, clinics, and distributors. BIOLASE’s principal executive offices are in Lake Forest, California. The company’s origins date back to 1984, when it was founded in Marseille, France, under the name Societe Endo Technic, SA. It later went through a corporate evolution in the United States, becoming BIOLASE Technology, Inc. in 1994 and BIOLASE, Inc. in 2012. That history is relevant for investors because it shows a long-standing technological and commercial orientation toward laser dentistry rather than a broad, diversified medtech platform. BIOLASE’s product portfolio is built around the Waterlase family of all-tissue dental lasers and the Epic line of soft-tissue diode lasers. Waterlase systems are positioned for hard tissue, soft tissue, and bone indications, while Epic products address soft-tissue surgery, hygiene procedures, pain therapy, and whitening. The company’s value proposition is straightforward: help dentists perform minimally invasive procedures that can reduce discomfort, bleeding, and recovery time, while expanding the range of procedures a practice can offer. In commercial terms, this supports both patient appeal and practice economics. From a competitive standpoint, BIOLASE is a specialist rather than a broad-based dental equipment manufacturer. Its market position depends on product differentiation, clinical credibility, intellectual property, and the ability to convert dentists to laser-based workflows. The company has historically emphasized its installed base and international reach, stating that it has sold products in more than 80 countries. That gives it geographic breadth, even though the United States remains a key market and its financial reporting and capital-markets activity are centered on the U.S. Recent developments matter for investors. BIOLASE has continued to raise capital through equity financings, including transactions in late 2023 and early 2024, reflecting ongoing funding needs. Its 2023 annual report disclosed recurring losses and a going-concern warning, underscoring balance-sheet pressure and execution risk. At the same time, BIOLASE has continued to refresh its product messaging, including the latest Waterlase iPlus generation and trade-show demonstrations focused on periodontal and implant care. Overall, BIOLASE remains a highly focused dental-laser player on the NASDAQ in the United States, with technology differentiation but material financial and liquidity challenges.